111 related articles for article (PubMed ID: 34778497)
1. SARS-CoV-2: A potential trigger of dermato-neuro syndrome in a patient with scleromyxedema.
Fritz M; Tinker D; Wessel AW; Morris GM; Goldenberg L; Fesler M; Rukmangadachar L; Hurley MY
JAAD Case Rep; 2021 Dec; 18():99-102. PubMed ID: 34778497
[No Abstract] [Full Text] [Related]
2. Dermato-neuro syndrome after COVID-19 infection in a patient with scleromyxoedema: Previously successful treatment with intravenous immunoglobulins.
Li Y; Wang H; Wang A; Zhao G
J Dermatol; 2024 Jan; 51(1):140-144. PubMed ID: 37830263
[TBL] [Abstract][Full Text] [Related]
3. [Dermato-neuro syndrome-an acute and life-threatening complication of scleromyxedema Arndt-Gottron].
Linse KP; Enk A; Hoffmann J
Dermatologie (Heidelb); 2023 Aug; 74(8):618-620. PubMed ID: 37284981
[TBL] [Abstract][Full Text] [Related]
4. [Dermato-neuro syndrome during scleromyxedema: efficacy of plasmapheresis and intravenous immunoglobulin].
Charles S; Hainaut E; Cante V; Valette C; Levillain P; Guillet G
Ann Dermatol Venereol; 2014; 141(8-9):523-7. PubMed ID: 25209816
[TBL] [Abstract][Full Text] [Related]
5. [Good response of scleromyxedema and dermato-neuro syndrome to treatment with intravenous immunoglobulins].
Bielsa I; Benvenutti F; Guinovart RM; Ferrándiz C
Actas Dermosifiliogr; 2012 May; 103(4):317-20. PubMed ID: 21917233
[TBL] [Abstract][Full Text] [Related]
6. Dermato-neuro syndrome in a case of scleromyxedema.
Savran Y; Akarsu S
Eur J Rheumatol; 2015 Dec; 2(4):160-162. PubMed ID: 27708955
[TBL] [Abstract][Full Text] [Related]
7. [Monoclonal immunoglobulin (M-Ig) and skin diseases from the group of mucinoses--scleredema adultorum Buschke and scleromyxedema. Description of four cases and an overview of therapies].
Adam Z; Szturz P; Krejčí M; Vašků V; Pour L; Michalková E; Ševčíková S; Čermáková Z; Veselý K; Vaníček J; Pourová E; Král Z; Mayer J
Vnitr Lek; 2015 Dec; 61(12):1072-87. PubMed ID: 26806503
[TBL] [Abstract][Full Text] [Related]
8. Scleromyxedema and the dermato-neuro syndrome: case report and review of the literature.
Fleming KE; Virmani D; Sutton E; Langley R; Corbin J; Pasternak S; Walsh NM
J Cutan Pathol; 2012 May; 39(5):508-17. PubMed ID: 22515222
[TBL] [Abstract][Full Text] [Related]
9. Scleromyxedema.
Hoffmann JHO; Enk AH
J Dtsch Dermatol Ges; 2020 Dec; 18(12):1449-1467. PubMed ID: 33373143
[TBL] [Abstract][Full Text] [Related]
10. Scleromyxedema with dermato-neuro syndrome.
Gonzalez J; Palangio M; Schwartz J; Klainer AS; Bisaccia E
J Am Acad Dermatol; 2000 May; 42(5 Pt 2):927-8. PubMed ID: 10767707
[TBL] [Abstract][Full Text] [Related]
11. Acute Encephalitic Syndrome Induced by Scleromyxedema.
Magira EE; Malouchou A; Karathanasi V; Mavropoulou N; Siempos II; Vourlakou C; Sykaras A; Anastasiadis G
Am J Med Sci; 2020 Aug; 360(2):192-195. PubMed ID: 32540147
[TBL] [Abstract][Full Text] [Related]
12. Fever, convulsions and coma in scleromyxedema: a "dermato-neuro syndrome".
River Y; Levy I; Gilead L; Orbach H; Almog Y
Neurology; 1996 Jun; 46(6):1778-9. PubMed ID: 8649597
[No Abstract] [Full Text] [Related]
13. Scleromyxedema complicated by dermato-neuro syndrome during pregnancy.
Da Silva Domingues V; Iaccarino L; Briani C; Caso F; Vasconcelos C; Doria A
Clin Exp Rheumatol; 2014; 32(6 Suppl 86):S-234-5. PubMed ID: 25372807
[No Abstract] [Full Text] [Related]
14. Plasma cell-directed therapies in monoclonal gammopathy-associated scleromyxedema.
Mahévas T; Arnulf B; Bouaziz JD; Livideanu CB; Osio A; Servy A; Cribier B; Sassolas B; Jachiet M; Michel L; Aucouturier P; Lipsker D; Frances C; Sbidian E; Rybojad M; Descamps V; D'Incan M; Humbert P; Beylot-Barry M; Passeron T; de Moreuil C; Taha RY; Hermine O; Dupuy A; Barbarot S; Debarbieux S; Carpentier O; Brault F; Schmutz JL; Thomas-Beaulieu D; Modiano P; Zarnitsky C; Lifermann F; Baubion E; Limal N; Le Bras F; Le Moigne M; Tauber M; Talbot A; Prud'homme R; Peltier S; De Masson A; Battistella M; Bagot M; Mékinian A; Fain O
Blood; 2020 Apr; 135(14):1101-1110. PubMed ID: 32027747
[TBL] [Abstract][Full Text] [Related]
15. Combination oral prednisone and intravenous immunoglobulin in the treatment of scleromyxedema.
Majeski C; Taher M; Grewal P; Dytoc M; Lauzon G
J Cutan Med Surg; 2005 Jun; 9(3):99-104. PubMed ID: 16392012
[TBL] [Abstract][Full Text] [Related]
16. Dermato-neuro Syndrome after COVID-19 Vaccination in a Patient with Scleromyxoedema Previously Controlled with Bortezomib and Intravenous Immunoglobulins.
Gallo R; Trave I; Cotzia E; Russo R; Parodi A
Acta Derm Venereol; 2022 Dec; 102():adv00836. PubMed ID: 36511333
[No Abstract] [Full Text] [Related]
17. Scleromyxedema (papular mucinosis) with dermato-neuro syndrome: a rare, potentially fatal complication.
Landais AF; Duchemin CM; Bourhis VM
Presse Med; 2015; 44(7-8):850-1. PubMed ID: 26051450
[No Abstract] [Full Text] [Related]
18. An interstitial granulomatous pattern in scleromyxedema with dermato-neuro syndrome.
Akarsu S; Ozbagcivan O; Ilknur T; Lebe B; Fetil E
J Eur Acad Dermatol Venereol; 2016 Apr; 30(4):687-9. PubMed ID: 25640815
[No Abstract] [Full Text] [Related]
19. Dermato-neuro syndrome in a patient treated with autologous stem cell transplant for scleromyxedema.
Shams SR; Goldstein DA; Kaufman JL; MacKelfresh J; Flowers CR; Langston AA
Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):e213-5. PubMed ID: 25065780
[No Abstract] [Full Text] [Related]
20. Dermato-neuro syndrome associated with scleromyxedema.
Karaman B; Guler A; Ertam I; Celebisoy N
Indian J Dermatol Venereol Leprol; 2015; 81(5):519-21. PubMed ID: 26261151
[No Abstract] [Full Text] [Related]
[Next] [New Search]
